Cyclazodone

Pre-existing QTc prolongation or cardiac arrhythmia is an absolute contraindication. The sole clinical case involving cyclazodone exposure (as metabolite of N-methyl-cyclazodone) demonstrated critical QTc prolongation to 526 ms and QRS widening to 140 ms, indicating both repolarization and depolarization cardiac risks. Individuals with baseline conduction abnormalities face compounded arrhythmia risk.

Pre-existing cardiovascular disease is a relative contraindication. As a catecholaminergic stimulant, cyclazodone is expected to produce tachycardia and hypertension as dose-dependent pharmacological effects. One user report describes heart rate reaching 200 BPM at high doses. Individuals with coronary artery disease, heart failure, or uncontrolled hypertension face elevated risk.

Pre-existing seizure disorders are a relative contraindication. While stimulant effects on seizure threshold are variable across the class, the QRS widening observed in the N-methyl-cyclazodone case suggests possible sodium channel interaction, and the combination with seizure threshold-lowering drugs (tramadol) is designated lethal. Absence of data warrants caution.

A history of stimulant-induced psychosis is a relative contraindication. As a dopaminergic stimulant, cyclazodone carries class-level risk of precipitating psychotic episodes, particularly at strong or heavy doses or in combination with sleep deprivation. No cyclazodone-specific psychosis cases have been published.

Pre-existing hepatic impairment or liver disease is an absolute contraindication. Pemoline, the closest structural analog (differing only at the N-2 position), caused fatal idiosyncratic hepatotoxicity in at least 21 patients and was withdrawn from market. Whether cyclazodone retains this hepatotoxic liability is unknown but cannot be excluded given minimal structural divergence. ALT elevation was documented in the sole clinical case involving cyclazodone as a metabolite.

Pregnancy is an absolute contraindication on precautionary grounds. No reproductive toxicology, teratogenicity, or lactation data exist for cyclazodone. Catecholaminergic stimulants as a class pose risks to fetal cardiovascular development and placental perfusion.

Concurrent use of any monoamine oxidase inhibitor (MAOI) is an absolute contraindication. As a norepinephrine-dopamine reuptake inhibitor, cyclazodone combined with MAO inhibition would produce dangerous accumulation of synaptic catecholamines, risking hypertensive crisis, hyperthermia, and potentially fatal cardiovascular collapse. This is a universal class contraindication for all monoamine reuptake inhibitors.

Concurrent tramadol use is designated as a lethal-severity interaction. Tramadol's dual action as a weak opioid agonist and serotonin-norepinephrine reuptake inhibitor, combined with its seizure threshold-lowering properties, creates multiple overlapping toxicity mechanisms when combined with cyclazodone's catecholaminergic stimulation. Fatal outcomes have been documented with tramadol combined with other noradrenergic/serotonergic agents.

Concurrent SSRI use is a relative contraindication. The sole clinical case involved concurrent fluoxetine, which may have contributed to the observed toxicity through CYP2A6 inhibition (altering N-methyl-cyclazodone/cyclazodone metabolism) and additive monoaminergic burden. The interaction profile is uncharacterized but potentially serious.